Vilceanu, D., Honore, P., Hogan, Q
In 2021 - 2022, a stronger dose, weekly injectable formulation of Semaglutide (brand name Wegovy) was approved by the US FDA as a medication for weight loss in patients with at least one weight related medical issue
Some patients respond better to one over the other
Tirzepatide also affected proteins involved in neurotransmission, such as solute carrier family 6 member 6 (SLC6A6), reticulon 3 (RTN3), proline-rich transmembrane protein 2 (PRRT2), alpha-aminoadipic semialdehyde synthase (AASS), and microtubule-associated protein 1A (MAP1A)
Other regulatory bodies like the TGA and EMA typically follow within 12 to 18 months of FDA approval, though they run their own independent review processes
Quick Answer: GLP-1 receptor agonists are not licensed or recommended for treating high cortisol and should not be used for this purpose